IGFBP5 and esophageal cancer: Similarly, in esophageal cancer, cisplatin resistant cells have lower IGFBP5 relative to cisplatin sensitive cells, and reintroducing IGFBP5 resulted in a 41% reduction in acquired cisplatin resistance (119).